GLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters

GLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters

(MedPage Today) -- SAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric surgery, a retrospective analysis found. In 568 patients who underwent bariatric surgery, those who...

Small Molecules Unlock Big Opportunities in GLP-1R Drug Development

GLP-1R agonists have reshaped the treatment landscape for diabetes and obesity—and are now being explored across a range of new indications. In this article, we highlight notable clinical programs, from injectable peptides like semaglutide to oral small molecules like orforglipron, comparing their mechanisms, efficacy, and stage of development. We also explore the rising therapeutic and commercial value of GLP-1R as a $150B+ target, and examine …

Sai Life Sciences: GLP-1 boom 'exploded peptide field'

Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in… The post Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm o…

Why More People Are Choosing GLP-1 Over Fad Diets and Supplements

In a world full of overhyped pills, detox teas, and weight loss fads, many people are finally turning their attention to something scientifically grounded: hormone-based therapies. GLP-1 is one such hormone that is at the forefront. GLP-1, which is present in drugs like semaglutide and tirzepatide, significantly reduces appetite and aids in blood sugar regulation. Many people are wondering about this breakthrough: Can one hormone really curb app…

Wicked Good Cardiometabolic Chat: Semaglutide’s Expanding Role in Chronic Disease

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Bariatric outcomes of high BMI patients with preoperative anti-obesity medications

Treating severe obesity (BMI > 50 kg/m2) poses unique challenges. Glucagon-like peptide-1 (GLP-1) receptor agonists have shown